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ABSTRACT
Background and objective There is little evidence
that electronic medical record (EMR) use is associated
with better compliance with clinical guidelines on
initiation of antiretroviral therapy (ART) among
ART-eligible HIV patients. We assessed the effect of
transitioning from paper-based to an EMR-based system
on appropriate placement on ART among eligible
patients.
Methods We conducted a retrospective, pre-post EMR
study among patients enrolled in HIV care and eligible
for ART at 17 rural Kenyan clinics and compared the:
(1) proportion of patients eligible for ART based on CD4
count or WHO staging who initiate therapy; (2) time
from eligibility for ART to ART initiation; (3) time from
ART initiation to first CD4 test.
Results 7298 patients were eligible for ART; 54.8%
(n=3998) were enrolled in HIV care using a paper-based
system while 45.2% (n=3300) were enrolled after the
implementation of the EMR. EMR was independently
associated with a 22% increase in the odds of initiating
ART among eligible patients (adjusted OR (aOR) 1.22,
95% CI 1.12 to 1.33). The proportion of ART-eligible
patients not receiving ART was 20.3% and 15.1% for
paper and EMR, respectively (χ2=33.5, p<0.01). Median
time from ART eligibility to ART initiation was 29.1 days
(IQR: 14.1–62.1) for paper compared to 27 days (IQR:
12.9–50.1) for EMR.
Conclusions EMRs can improve quality of HIV care
through appropriate placement of ART-eligible patients
on treatment in resource limited settings. However, other
non-EMR factors influence timely initiation of ART.
INTRODUCTION
Electronic medical record (EMR) systems have
been shown to significantly improve the quality of
healthcare through improved availability of high
quality data for clinical decision making.1 2
Additionally, EMRs improve adherence to treat-
ment guidelines, resulting in better management of
chronic illnesses3 4 which often require collection
of complex data that is longitudinal.5 The easy
retrieval of electronic data and automated reports
through EMRs can provide information on compli-
ance or non-compliance with key conditions in the
clinical guidelines and timeliness of laboratory tests
to monitor disease progression and response to
treatment.4 Studies conducted in sub-Saharan
Africa (SSA) have shown improvement in time-
dependent events following the introduction of
EMRs, such as time to process and analyze labora-
tory specimens, patient waiting time, and duration
of hospitalization.5–7 Expansion of health systems
in many African countries has been hampered by
weak infrastructure, lack of adequate skilled health
workers, lack of or poor policies, and inadequate
funding. EMRs provide a unique opportunity to
enhance clinical care by integrating systems that
have been demonstrated to work in developed
countries.8 9 As HIV remains a major public health
problem in SSA, which is home to two-thirds of
the world’s 34 million HIV-infected persons, sub-
stantial global funding for the management of this
disease has led to increased investment in EMRs in
order to manage the complex data for monitoring
the lifelong treatment of those infected.10 11
The wide-scale availability of antiretroviral
therapy (ART) has significantly reduced HIV-related
morbidity and mortality since 2000.12–14 As of
December 2011, 54% of 14.8 million patients eli-
gible for ART globally were receiving ART. The
majority (75%, n=6 million) of those receiving
ARTwere in SSA.14 As of September 2012, approxi-
mately 600 000 patients were receiving ART out of
1.5 million HIV-infected persons in Kenya.15 WHO
guidelines define conditions for ART eligibility
based on the clinical presentation of the patient
(WHO staging) and on the immunological status
assessed using CD4 T-cell count.16–18 Despite the
global decline in mortality among HIV-infected
patients, the number of deaths still remains high in
SSA as many eligible patients are not initiated on
ART or are initiated late, when the disease is in
advanced stages. This is evident through advanced
clinical signs or low baseline CD4 T-cell count indi-
cative of a weakened immune system.19 Although
CD4 T-cell count testing is a routine laboratory
measurement for patients enrolled in HIV care pro-
grams, test results are not always available for clin-
ical management of patients due to breakdown of
flow cytometry equipment, lack of reagents, or poor
recording and can contribute to late or inappropri-
ate initiation of ART.20 21 Clinicians may also fail to
recognize immunological treatment failure which
may delay necessary changes in ARTregimens.
There is no published evidence that EMRs can
improve adherence to clinical guidelines on place-
ment of ART-eligible patients on treatment in
resource-limited settings. The purpose of this study
was to assess the effect of transitioning from the
use of paper-based to an EMR-based system for
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HIV patient data management on timely initiation of ART
among eligible patients and timely performance of CD4 T-cell
count test as described in the Kenya national HIV treatment
guidelines.22
METHODS
This study was conducted at 17 out of 122 rural health facilities
in Siaya County in Western Kenya providing HIV care and treat-
ment services. The 17 government-owned clinics are among 20
facilities where the Kenya Medical Research Institute (KEMRI)
provides data management and information and communica-
tions technology (ICT) support. Three clinics that were
excluded from this study did not have electric power or a secure
location for a computer at the time of the study. All these facil-
ities have transitioned from the use of paper-based to
EMR-based systems for management of patient data. EMRs
were installed at the facilities on varying dates between
September 2009 and June 2012. The clinics included four dis-
trict hospitals (level 4, headed by a physician and provides full
inpatient and outpatient care, offering access to select specia-
lized services), 11 health centers (level 3, headed by a clinical
officer and provides the lowest level of inpatient care, in add-
ition to outpatient and maternity services), and two dispensaries
(level 2, headed by a nurse and provides the lowest level of
facility-based outpatient services).23
ART eligibility and appropriate placement of patients
on ART
The Kenyan Ministry of Health (K-MOH) guidelines for ART22
were adapted from the WHO guidelines which were published
in 2007 and revised in 2010.24 The K-MOH guidelines recom-
mend using the patient’s clinical status (WHO staging) and CD4
cell count as key determinants when assessing eligibility for
placement of patients on ART. In this paper, appropriate place-
ment refers to the guideline-based initiation of ART among eli-
gible patients.
WHO clinical staging
The WHO clinical staging uses clinical parameters to categorize
HIV infection into four stages that reflect disease severity and
prognosis.18 24 WHO clinical stages I and II are often associated
with early HIV infection and manifest as conditions such as
minor skin diseases and upper respiratory tract infections.
WHO clinical stages III and IV are associated with advanced
HIV disease and may manifest as one or more diseases such as
extrapulmonary tuberculosis, esophageal candidiasis, or Kaposi
sarcoma and are used to confirm eligibility for initiation of ART.
WHO staging is used mainly to help clinicians make decisions
on ART eligibility in health facilities which have no immediate
access to CD4 T-cell count testing.
CD4 T-cell count and ART eligibility
CD4 T-cell counts serve as the most important laboratory-based
measurement of the state of immunosuppression among patients
with HIV and is a main prognostic indicator of patients starting
ART.22 The current K-MOH guidelines, which were implemen-
ted in 2011, recommend ART initiation among patients aged
2 years or older with the following conditions: (i) CD4
≤350 cells/mL, and stage I or II disease; and (ii) WHO stage III
and IV irrespective of CD4 cell count. The K-MOH guidelines
recommend initiation of ART for all HIV-infected children
under the age of 2 years, irrespective of immunological status
measured using CD4 T-cell counts.
Study population
The study population consisted of male and female patients
aged 2 years or older, enrolled in HIV care not more than
1 year prior to the implementation of an EMR at the clinic. For
example, we excluded patients enrolled in HIV care before June
2008 at clinics where an EMR was installed in June 2009. We
also excluded ART-eligible patients who were initiated on ART
within 2 months of EMR installation as we considered this to be
the learning and transition period. Finally, we excluded patients
who had already initiated ART treatment elsewhere prior to
transferring into the participating health facility due to unavail-
ability of data on baseline CD4 measurements prior to ART ini-
tiation and date of ARTeligibility.
Paper-based system
In the paper-based system, patient data were captured using a
K-MOH approved Comprehensive Care Clinic Card (MOH
257) which collected data on: demographic and contact details
of the patient, treatment support information, HIV testing and
treatment history, allergies, HIV treatment eligibility and ART
regimen (first or second line ART), vital signs, co-infections
(including tuberculosis screening and treatment status and other
opportunistic infections), laboratory test results for treatment
monitoring (including CD4 T-cell counts, hemoglobin, and
alanine aminotransferase (ALT)), treatment outcomes (including
death, transfer-out, loss to follow-up, and interrupted treat-
ment), and appointment date for the next visit. Additional notes
were recorded on plain paper and filed together with the MOH
257 in the patient charts.
Treatment data from MOH 257 were manually transcribed
into the national ART register, and used mainly to provide
summary statistics for routine reporting to K-MOH. The date of
next visit recorded on the MOH 257 was used for scheduling
patient visits for each clinic day. The clinicians read through the
patient notes during each clinic visit to review trends in vital
signs, patient promptness with appointments, CD4 T-cell
counts, and other laboratory-based treatment monitoring
parameters.
Transition to EMR system
The EMR system, also referred to as Comprehensive Care
Centre Patient Application Database (C-PAD), was developed in
2007. The C-PAD EMR version used for this study was a stan-
dalone application developed using Visual Basic for Applications
(VBA) and an MS-Access database.
Clinicians record data on the paper-based MOH 257 form
during each patient encounter. Each clinic has a data entry clerk
who enters these data into C-PAD immediately after the visit.
These data are used to generate summary reports that are avail-
able for the clinician’s review during the weekly clinical review
meetings that are also attended by nurses and data clerks. The
system has been programmed to ensure that mandatory variables
such as demographic data, vital signs, medication, and key
laboratory measurements are entered. If these essential variables,
including demographic data, vital signs, medication, and labora-
tory measurements were missing from the MOH 257 form, the
data clerks contacted the clinician to ensure that missing data
were provided and entered into the EMR, as functionally
required by the EMR system. To update the system’s database,
historical treatment data from the paper-based system were
entered retrospectively for all patients who had been initiated
on treatment prior to the EMR system installation.
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For comparison purposes, retrospective data from the paper
systems were entered into the C-PAD system at the participating
health facilities.
Outcome measures
The following outcomes were analyzed to measure the quality
of HIV care received: (1) proportion of patients eligible for
ART based on CD4 count or WHO clinical staging who initiate
therapy; (2) time from eligibility for ART to actual ART; and (3)
time from ART initiation to the first CD4 T-cell count test fol-
lowing ART.
We compared these outcomes before (paper-based system)
and after (C-PAD EMR) the EMR system was introduced in the
facilities. For each site, the date of C-PAD installation was used
to compare the outcome measures during the paper-based
versus the EMR based data management.
Statistical analysis
We included records of patients that were eligible for ART
based on the Kenyan ART treatment guidelines.22 We excluded
patients that did not have an ART eligibility date but had an
ART initiation date, and records with an earlier date of ART ini-
tiation compared to the ART eligibility date. We included
records of patients who were enrolled in HIV care using a
paper-based system and who subsequently became eligible for
ART after the installation of EMRs since the duration of
follow-up for the majority of these patients was much longer on
the paper system than follow-up on EMR before they became
eligible for ART.
In univariate analysis, frequencies and proportions were
reported for categorical variables and median and IQR were
reported for continuous variables. The survivor function meas-
urement was used to calculate median time to event. Patients
who had not encountered the anticipated time-based events
were censored on the date of the last visit. Kaplan–Meier sur-
vival graphs were used to compare time-to-event analysis (time
from eligibility to ART initiation and time from ART initiation
to first CD4 cell count) between the paper-based and the EMR
system. The log rank test of equality was used to test for differ-
ences in the rate of occurrence of the time-based events between
the paper-based system and the EMR system. Pearson’s χ2 test
was used to test for the statistical difference between propor-
tions of eligible patients that were not receiving ART (under-
treated) and those that were receiving ART, before and after
implementation of the EMR system.
Potential associations between EMR use and ART initiation
were also assessed in bivariate analysis using logistic regression
expressed as OR and corresponding 95% CIs. All variables in
table 2 were entered into a multiple logistic regression model,
irrespective of their statistical significance level, to identify predi-
cators that were independently and significantly associated with
EMR use and ART initiation. Cox proportional hazards regres-
sion models, expressed in HRs and corresponding 95% CI, were
used to identify factors associated with time to ART initiation
and time to CD4 cell count test. All variables in table 2 were
entered into a Cox proportional hazards regression model, irre-
spective of their statistical significance level, to test for factors
independently associated with the time from eligibility for ART
to initiation of ART and time to first CD4 T-cell test using
adjusted HRs (aHRs) and corresponding 95% CI. We allowed
for potential site-level clustering using generalized estimating
equations in the logistic and Cox regression models. Stata V.12.1
was used to perform the statistical analysis.
Ethical considerations
The study was approved by the Associate Director for Science at
the Division of Global HIV/AIDS of the US Centers for Disease
Control and Prevention (CDC) and the KEMRI institutional
review board. Individual patient data were de-identified by the
KEMRI staff responsible for primary data collection prior to
analysis.
RESULTS
Of the 11 637 patients aged 2 years or older enrolled in HIV
care programs not more than 1 year prior to the implementation
of the EMR, a total of 7308 patients were eligible for ART
based on their CD4 T-cell count or WHO staging. We further
excluded records from one patient who had no ART eligibility
date but had an ART initiation date. In addition, we excluded
nine records that had an earlier ART initiation date than the
date of ART eligibility. Among the remaining 7298 eligible
patients, 54.8% (n=3998) were enrolled in HIV care using a
paper-based system while 45.2% (n=3300) were enrolled after
the implementation of an EMR (table 1). In total, 5990 (82.1%
of eligible patients) were receiving ART, including 3595 (60.0%)
women and 2395 (40.0%) men. The median age of patients
enrolled using paper based systems was 31.6 years (IQR: 25.3–
40.3) compared to 31.6 years (IQR: 24.8–40.5) for patients
enrolled after transitioning to EMR. Median baseline CD4
T-cell count after enrollment in HIV care was 324 cells/mL
(IQR: 202–486).
ART initiation among eligible patients
Use of EMR was significantly associated with an improved ART
initiation among patients compared to the paper-based system
(OR=1.44, 95% CI 1.23 to 1.68) (table 2). After adjusting for
patient’s sex, age, WHO stage, and level of health facility, EMR
was independently associated with a 22% increase in the odds
of initiating ART among eligible patients (aOR=1.22, 95% CI
1.12 to 1.33) compared to paper-based systems. After excluding
the six clinics that had no patients eligible for ART during the
data collection period (facility IDs 12, 13, 14, 15, 16, and 17)
the odds of ART initiation among eligible patients was
OR=1.49 (95% CI 1.28 to 1.71) and aOR=1.21 (95% CI 1.10
to 1.32).
During the period in which the facility used the paper-based
system, 20.3% (n=811) of patients were eligible for ART but
were not receiving ART versus 15.1% (n=497) of patients who
were eligible for ART after implementation of EMR system
(χ2=33.5; p<0.01).
Time from ART eligibility to actual initiation of ART
The median time from ARTeligibility to initiation was 29.1 days
(IQR: 14.1–62.1) in the paper-based system compared to
27 days (IQR: 12.9–50.1) in the EMR system. The median time
to ART initiation remained unchanged after excluding the
clinics with no patients eligible for ART. However, the IQR got
narrower in the paper group. Median time (excluding facility ID
12, 13, 14, 15, 16, and 17) was 29.1 days (IQR: 30.0–63.9) for
paper, and 27.0 days (IQR: 12.9–50.1) for EMR. Of the
patients eligible for ART, 84.5% (95% CI 82.4% to 86.4%) had
initiated ART 3 months from date of eligibility using the paper-
based system compared to 90.2% (95% CI 88.4% to 91.7%)
using the EMR system (figure 1). EMR use was associated with
a 25% increase in HR of initiation of ART among eligible
patients (HR=1.25; 95% CI 1.02 to 1.52). After adjusting for
patient’s sex, age, WHO stage, and level of health facility, the
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adjusted HR of ART initiation after implementation of an EMR
was 1.36 (95% CI 1.20 to 1.53).
Time from ART initiation to first CD4 test following
initiation
Among the 5990 patients receiving ART, 3458 (57.7%) had at
least one CD4 T-cell count test after initiation of ART. The
median time from ART initiation to first CD4 T-cell count test
was 6.27 months (IQR: 4.27–10.70) and 6.17 months (IQR:
4.63–11.43) for paper and EMR based systems, respectively. Six
months after ART initiation, 46.1% (95% CI 44.0% to 48.2%)
of the patients receiving ARTand enrolled using the paper-based
system had had at least a CD4 T-cell count test compared to
45.5% (95% CI 43.1% to 47.9%) of patients using the EMR
system (figure 2). EMR use was not significantly associated with
the hazard of conducting the first CD4 test after initiation of
ART (HR=0.94, 95% CI 0.68 to 1.28). After adjusting for sex,
age, WHO stage, and facility level, aHR=0.98 (95% CI 0.74
to 1.28).
DISCUSSION
EMR use was associated with a 22% increase in the odds of
ART initiation among eligible patients enrolled into HIV care
after transitioning from a paper-based system. Although the
study showed a 7% reduction in the time from ARTeligibility to
ART initiation following the introduction of an EMR (from
29.1 days down to 27 days), this was not clinically significant.
The study also showed that about 80% of patients eligible for
ART had been initiated on therapy. Although this proportion is
higher than the 56% coverage that UNAIDS reported for SSA at
Table 1 Number of patients, by health facility, enrolled on HIV care, eligible for antiretroviral therapy (ART) and those initiated on ART using





















1 3 11/1/2011 114 62 58 (93.5) 55 30 29 (96.7)
2 4 8/1/2010 1343 875 717 (81.9) 1153 700 627 (89.6)
3 2 10/1/2011 208 127 101 (79.5) 37 11 10 (90.9)
4 4 12/1/2009 601 356 296 (83.1) 886 455 400 (87.9)
5 3 11/1/2011 101 55 53 (96.4) 46 22 20 (90.9)
6 3 12/1/2010 232 161 144 (89.4) 284 189 159 (84.1)
7 2 10/1/2011 253 126 118 (93.7) 49 18 15 (83.3)
8 3 8/1/2010 595 349 297 (85.1) 308 176 158 (89.8)
9 4 9/1/2009 1478 1082 802 (74.1) 1743 1164 961 (82.6)
10 3 11/1/2011 204 100 84 (84.0) 20 3 3 (100.0)
11 4 12/1/2009 658 506 340 (67.2) 844 532 421 (79.1)
12 3 6/1/2012 1 1 0 (0.0) 0 0 0 (0.0)
13 3 6/1/2012 96 60 54 (90.0) 0 0 0 (0.0)
14 3 6/1/2012 159 61 55 (90.2) 6 0 0 (0.0)
15 3 7/1/2012 30 20 14 (70.0) 1 0 0 (0.0)
16 3 6/1/2012 73 33 30 (90.9) 0 0 0 (0.0)
17 3 7/1/2012 59 24 24 (100.0) 0 0 0 (0.0)
Total 6205 3998 3187 (79.7) 5432 3300 2803 (84.9)
*Facility level: 2, dispensary; 3, health center; 4, district hospital. A detailed description of facility types is provided in the Methods section.
†The percentages in parentheses are calculated using the number of patients initiated on ART as the numerator, and the number of patients eligible for ART as the denominator.
Table 2 Association between electronic medical record (EMR) and antiretroviral therapy (ART) initiation among eligible patients, location, year
Variable
ART initiation
OR (95% CI) p Value Adjusted OR (95% CI) p Value
Paper based system Ref Ref
EMR system 1.44 (1.23 to 1.68) <0.01 1.22 (1.16 to 1.33) <0.01
Male Ref Ref
Female 1.22 (1.10 to 1.36) <0.01 1.04 (0.91 to 1.18) 0.35
Age (years) 1.00 (1.00 to 1.00) 0.53 1.01 (1.00 to 1.01) <0.01
WHO stage 1 Ref Ref
WHO stage 2 0.93 (0.30 to 2.84) 0.89 0.91 (0.25 to 3.35) 0.89
WHO stage 3 0.01 (0.00 to 0.05) <0.01 0.16 (0.00 to 0.05) <0.01
WHO stage 4 0.01 (0.00 to 0.03) <0.01 0.01 (0.00 to 0.04) <0.01
Level 2 facility Ref Ref
Level 3 facility 1.12 (0.53 to 2.38) 0.76 1.07 (0.90 to 1.28) 0.46
Level 4 facility 0.64 (0.29 to 1.41) 0.27 0.79 (0.68 to 0.92) <0.01
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the end of 2011,14 some 20% of eligible patients are still not
receiving ART which may mean under-treatment of these
patients. Although EMR use was not significantly associated
with a reduction in time to conduct a CD4 T-cell test following
ART initiation, the duration using both paper and EMR systems
was comparable to the 6 months recommended in the K-MOH
treatment guidelines.22
EMR use increased the chances of patients turning up at the
clinic for ART initiation but not how fast they came. The differ-
ence in time from ART eligibility to ART initiation between the
EMR and paper groups was marginal, suggesting that EMR use
did not influence timely initiation of ART despite the weekly
generated list of eligible patients that were not receiving treat-
ment. Non-EMR factors such as clinician behavior (provider
practice)25 26 and the time for preparation of patients for ART,
which includes adherence counseling prior to ART initiation to
improve compliance to the treatment regimen22 and the
patient’s own readiness to initiate ART, could have contributed
to the relatively unchanged time to treatment initiation. On the
other hand, without a reminder (whether lists generated by an
EMR or other systems), the need to thoroughly review patient
notes to verify eligibility can be overwhelming to clinicians who
may in some cases forget to initiate ARTamong eligible patients,
resulting in a missed opportunity for appropriate ART initiation.
This scenario is more likely in busy clinics or when the patient’s
clinical presentation does not indicate they are eligible for ART.
The missed opportunity of not providing appropriate treat-
ment to 22% of the 4000 patients using paper-based system
translates to 880 patients not being appropriately placed on
treatment. It has been shown that late initiation of treatment
results in poor outcomes, including increased mortality.27 Level
4 facilities seemed to be negatively associated with initiation of
ART among eligible patients. This could be due to the high
volume of patients receiving HIV care at these facilities served
by a small number of overworked clinicians.
A key strength of our study is that it was conducted at mul-
tiple sites using the same K-MOH ART guidelines, hence a large
sample size which improved the precision of the estimates. All
17 participating health facilities had similar administrative, man-
agerial, and laboratory procedures as well as drug regimens.
Our study was not without limitations. Since the retrospective
study was based on routinely collected data from rural health
facilities, we had challenges with the data quality; for example,
we excluded records that did not have an ART eligibility date
but had an ART initiation date, or those with an earlier date of
ART initiation than the ART eligibility date. Additionally, we
excluded from analysis records which had an eligibility date
later than the date of ART initiation. However, such records
were less than 1% of all the records included in the analysis and
therefore had minimal impact on the results. It was difficult to
determine whether patients that had no recorded ARTeligibility
date but were on therapy (n=10) were actually over-treated.
EMRs had only been in use for approximately 6 months in a
few facilities, which potentially impacted on data quality.
Appropriate initiation of ART as recommended in the clinical
guidelines is influenced by several factors such as clinician’s
practice, patient’s behavior and preference, and societal factors.
These factors potentially confounded the true association of
EMRs and ART initiation. The challenges reported in transition-
ing from paper to EMR systems were not unique to our study;
limited technical skills, poor data quality, and poor infrastruc-
ture (including frequent power outages) were also reported by
Fraser and Williams.8 9 Other temporal factors such as improved
knowledge of health workers and better access to CD4 T-cell
count testing equipment could have also contributed to the
observed improvements over time.
The benefits of EMR use in improving quality of care can
potentially be used to inform policies around the use of technol-
ogy based solutions in clinical settings in SSA. In an environ-
ment of stiff competition for resources, there is a need for
tangible evidence to convince decision makers to invest
resources in technologies that have been shown to improve effi-
ciency and adherence to treatment guidelines.
CONCLUSION
We found that EMRs can improve quality of HIV care through
appropriate placement of ART-eligible patients on treatment in
resource-limited settings. However, other non-EMR factors
influence timely initiation of ART. There is room for improve-
ment in adherence to clinical guidelines. Rigorous evaluation
studies are needed to demonstrate associations between decision
support systems implemented in EMRs and important quality of
HIV care indicators such as retention on treatment.
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